Clinical and Laboratory Indexes for Predicting Early and Late Responders to Lebrikizumab in Atopic Dermatitis: A Prospective Cohort Observational Study
Restricted accessResearch articleFirst published online 2025
Clinical and Laboratory Indexes for Predicting Early and Late Responders to Lebrikizumab in Atopic Dermatitis: A Prospective Cohort Observational Study
Abstract:Background: An anti-interleukin-13 antibody lebrikizumab is effective for atopic dermatitis (AD). However, predictive factors for responders to lebrikizumab are unknown in real-world practice.
Objective: To identify predictive factors for early and late responders to lebrikizumab treatment for AD.
Methods: A prospective study was conducted with 112 Japanese patients with AD who received lebrikizumab between May 2024 and February 2025. Early responders were defined as patients who achieved investigator’s global assessment (IGA) 0/1 at week 12, and late responders were defined as those who did not achieve IGA 0/1 at week 12 but achieved IGA 0/1 at week 24. We compared patients’ background factors and baseline clinical or laboratory indexes between responders and poor responders.
Results: Early responders showed lower baseline eczema area and severity index (EASI), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and platelet-to-lymphocyte ratio (PLR) while late responders showed lower baseline immunoglobulin E (IgE), eosinophil-to-lymphocyte ratio (ELR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), PLR, systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) compared with respective poor responders.
Conclusions: Patients with AD with lower baseline EASI, TARC, LDH, and PLR may predict early responses, while those with lower baseline IgE, ELR, NLR, MLR, PLR, SII, and SIRI may predict late responses to lebrikizumab.
Get full access to this article
View all access options for this article.
References
1.
Chiesa FuxenchZC, BlockJK, BoguniewiczM, et al.Atopic dermatitis in America study: A cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019; 139(3):583–590; doi: 10.1016/j.jid.2018.08.028
2.
HarropJ, ChinnS, VerlatoG, et al.Eczema, atopy and allergen exposure in adults: A population-based study. Clin Exp Allergy. 2007; 37(4):526–535; doi: 10.1111/j.1365-2222.2007.02679.x
HadiHA, TarmiziAI, KhalidKA, et al.The Epidemiology and Global Burden of Atopic Dermatitis: A Narrative Review. Life (Basel). 2021; 11(9); doi: 10.3390/life11090936
DiepgenTL, OfenlochRF, BruzeM, et al.Prevalence of contact allergy in the general population in different European regions. Br J Dermatol. 2016; 174(2):319–329; doi: 10.1111/bjd.14167
7.
HondaT, KabashimaK. Reconciling innate and acquired immunity in atopic dermatitis. J Allergy Clin Immunol. 2020; 145(4):1136–1137; doi: 10.1016/j.jaci.2020.02.008
8.
HaginoT, SaekiH, KandaN. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022; 49(11):1158–1167; doi: 10.1111/1346-8138.16549
9.
UchiyamaA, FujiwaraC, InoueY, et al.Possible suppressive effects of baricitinib on serum IL-22 levels in atopic dermatitis. J Dermatol Sci. 2022; 106(3):189–192; doi: 10.1016/j.jdermsci.2022.04.006
10.
KosakaK, UchiyamaA, IshikawaM, et al.Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study. Eur J Dermatol. 2022; 32(6):800–802; doi: 10.1684/ejd.2022.4365
11.
NomuraT, SandilandsA, AkiyamaM, et al.Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007; 119(2):434–440; doi: 10.1016/j.jaci.2006.12.646
12.
SilverbergJI. Atopic dermatitis in adults. Med Clin North Am. 2020; 104(1):157–176; doi: 10.1016/j.mcna.2019.08.009
13.
KamataM, TadaY. Optimal use of JAK inhibitors and biologics for atopic dermatitis on the basis of the current evidence. JID Innov. May 2023; 3(3):100195; doi: 10.1016/j.xjidi.2023.100195
14.
NakashimaC, YanagiharaS, OtsukaA. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022; 71(1):40–46; doi: 10.1016/j.alit.2021.10.004
15.
BieberT. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020; 75(1):54–62; doi: 10.1111/all.13954
16.
Marbach-BreitrückE, KalledatA, HeydeckD, et al.Atopic patients show increased interleukin 4 plasma levels but the degree of elevation is not sufficient to upregulate interleukin-4-sensitive genes. Skin Pharmacol Physiol. 2019; 32(4):192–200; doi: 10.1159/000499431
17.
SzegediK, LutterR, ResPC, et al.Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol. 2015; 29(11):2136–2144; doi: 10.1111/jdv.13160
18.
TubauC, PuigL. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Rev Clin Immunol. 2021; 17(1):15–25; doi: 10.1080/1744666x.2020.1858802
19.
TsoiLC, RodriguezE, DegenhardtF, et al.Atopic dermatitis is an il-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019; 139(7):1480–1489; doi: 10.1016/j.jid.2018.12.018
20.
SmithB, EngelP, WuJJ. Lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023; 388(24):2299; doi: 10.1056/NEJMc2304782
21.
LohTY, HsiaoJL, ShiVY. Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis. J Asthma Allergy. 2020; 13:109–114; doi: 10.2147/jaa.S211032
22.
BernardoD, BieberT, TorresT. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2023; 24(5):753–764; doi: 10.1007/s40257-023-00793-5
23.
LabibA, JuT, YosipovitchG. Managing atopic dermatitis with lebrikizumab—the evidence to date. Clin Cosmet Investig Dermatol. 2022; 15:1065–1072; doi: 10.2147/ccid.S295672
24.
UltschM, BeversJ, NakamuraG, et al.Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013; 425(8):1330–1339; doi: 10.1016/j.jmb.2013.01.024
25.
SilverbergJI, Guttman-YasskyE, ThaçiD, et al.; ADvocate1 and ADvocate2 Investigators. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023; 388(12):1080–1091; doi: 10.1056/NEJMoa2206714
26.
BlauveltA, ThyssenJP, Guttman-YasskyE, et al.Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023; 188(6):740–748; doi: 10.1093/bjd/ljad022
27.
SimpsonEL, GooderhamM, WollenbergA, et al.; ADhere Investigators. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: A randomized clinical trial (ADhere). JAMA Dermatol. 2023; 159(2):182–191; doi: 10.1001/jamadermatol.2022.5534
28.
Stein GoldL, ThaçiD, ThyssenJP, et al.Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. Am J Clin Dermatol. 2023; 24(4):595–607; doi: 10.1007/s40257-023-00792-6
29.
HebertAA, FlohrC, HongHC, et al.Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials. J Dermatolog Treat. 2024; 35(1):2324833; doi: 10.1080/09546634.2024.2324833
30.
YosipovitchG, LioPA, RosmarinD, et al.Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: Two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2024; 190(2):289–291; doi: 10.1093/bjd/ljad435
31.
SimpsonEL, FlohrC, EichenfieldLF, et al.Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. May 2018; 78(5):863–871.e11; doi: 10.1016/j.jaad.2018.01.017
32.
TanakaA, IgawaK, TakahashiH, et al.Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis. Acta Derm Venereol. 2024; 104:adv34375; doi: 10.2340/actadv.v104.34375
33.
SoungJ, StänderS, GutermuthJ, et al.Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials. J Dermatolog Treat. 2024; 35(1):2329240; doi: 10.1080/09546634.2024.2329240
34.
HaginoT, UchiyamaA, OndaM, et al.Real-World effectiveness and safety of lebrikizumab for moderate-to-severe atopic dermatitis: A 16-Week study in Japan. Dermatitis. 20 2025; doi: 10.1089/derm.2025.0004
35.
SaekiH, OhyaY, ArakawaH, et al.English version of clinical practice guidelines for the management of atopic dermatitis 2024. J Dermatol. 2025; 52(2):e70–e142; doi: 10.1111/1346-8138.17544
36.
DziedzicEA, GąsiorJS, TuzimekA, et al.Investigation of the associations of novel inflammatory biomarkers-systemic inflammatory index (SII) and systemic inflammatory response index (SIRI)-with the severity of coronary artery disease and acute coronary syndrome occurrence. Int J Mol Sci. 2022; 23(17); doi: 10.3390/ijms23179553
37.
SugimotoE, MatsudaH, ShibataS, et al.Impact of pretreatment systemic inflammatory markers on treatment persistence with biologics and conventional systemic therapy: A Retrospective study of patients with psoriasis vulgaris and psoriatic arthritis. J Clin Med. 2023; 12(8); doi: 10.3390/jcm12083046
38.
TopkanE, MertsoyluH, KucukA, et al.Low systemic inflammation response index predicts good prognosis in locally advanced pancreatic carcinoma patients treated with concurrent chemoradiotherapy. Gastroenterol Res Pract. 2020; 2020:5701949; doi: 10.1155/2020/5701949
39.
MaR, CuiL, CaiJ, et al.Association between systemic immune inflammation index, systemic inflammation response index and adult psoriasis: Evidence from NHANES. Front Immunol. 2024; 15:1323174; doi: 10.3389/fimmu.2024.1323174
40.
HaginoT, SaekiH, FujimotoE, et al.Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study. J Dermatol. May 2024; 51(5):649–658; doi: 10.1111/1346-8138.17186
41.
YangYL, WuCH, HsuPF, et al.Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. May 2020; 50(5):e13230; doi: 10.1111/eci.13230
42.
HaginoT, SaekiH, FujimotoE, et al.Predictive factors for poor responders to tralokinumab in moderate-to-severe atopic dermatitis: A real-world analysis. Dermatitis. 2025; 5; doi: 10.1089/derm.2024.0515
43.
HaginoT, SaekiH, FujimotoE, et al.Identification of early and late responders to anti-IL-13 antibody tralokinumab in atopic dermatitis: A real-world Japanese study. Dermatitis. 2024; doi: 10.1089/derm.2024.0460
44.
Renert-YuvalY, ThyssenJP, BissonnetteR, et al.Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021; 147(4):1174–1190.e1; doi: 10.1016/j.jaci.2021.01.013
45.
Crapster-PregontM, YeoJ, SanchezRL, et al.Dendritic cells and alveolar macrophages mediate IL-13-induced airway inflammation and chemokine production. J Allergy Clin Immunol. 2012; 129(6):1621–1627.e3; doi: 10.1016/j.jaci.2012.01.052
46.
Kido-NakaharaM, OnozukaD, IzuharaK, et al.Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis. J Allergy Clin Immunol Glob. 2024; 3(4):100317; doi: 10.1016/j.jacig.2024.100317
47.
SwindellWR, BojanowskiK, ChaudhuriRK. Isosorbide fatty acid diesters have synergistic anti-inflammatory effects in cytokine-induced tissue culture models of atopic dermatitis. Int J Mol Sci. 2022; 23(22); doi: 10.3390/ijms232214307
48.
FurueM, ChibaT, TsujiG, et al.Atopic dermatitis: Immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017; 66(3):398–403; doi: 10.1016/j.alit.2016.12.002
49.
ZhangL, PiJ, WangJ, et al.The association of inflammatory indexes derived from peripheral blood cell count and clinical signs with response to treatment with dupilumab in pediatric patients with moderate-to-severe atopic dermatitis. J Inflamm Res. 2025; 18:271–282; doi: 10.2147/jir.S501883
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
